Insider Transactions in Q4 2021 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+8.01%
|
$168,000
$6.15 P/Share
|
|
Dec 28
2021
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
3,400
-8.51%
|
$224,400
$66.82 P/Share
|
|
Dec 28
2021
|
Douglas B Given Director |
BUY
Open market or private purchase
|
Direct |
655
+0.59%
|
$43,230
$66.37 P/Share
|
|
Dec 28
2021
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
655
-0.6%
|
-
|
|
Dec 23
2021
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,806
+0.36%
|
$59,030
$5.19 P/Share
|
|
Dec 15
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
60,000
-0.37%
|
$4,080,000
$68.28 P/Share
|
|
Nov 19
2021
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,500
-5.16%
|
$1,365,000
$70.0 P/Share
|
|
Oct 22
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-0.75%
|
$3,250,000
$65.83 P/Share
|
|
Oct 20
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.45%
|
$990,000
$66.23 P/Share
|